The Jerusalem Post

Gene editing takes on new roles

- • By JUDY SIEGEL-ITZKOVICH

Anew combined method for gene editing may finally give scientists a tool fine enough to probe life’s most nuanced processes. What combinatio­ns of mutations help cancer cells survive? Which cells in the brain are involved in the onset of Alzheimer’s disease? How do immune cells conduct their convoluted decision-making processes? Researcher­s at the Weizmann Institute of Science in Rehovot have now combined two powerful research tools – CRISPR gene editing and single-cell genomic profiling – in a method that may finally help us get answers to these questions and many more.

The new technology enables researcher­s to manipulate gene functions within single cells, and understand the results of each change in extremely high resolution. A single experiment with this method, according to the scientists, may be equal to thousands of experiment­s conducted using previous approaches, and it may advance the field of genetic engineerin­g for medical applicatio­ns.

The gene-editing technique CRISPR is already transformi­ng biology research around the world, and its clinical use in humans is just around the corner. CRISPR was first discovered in bacteria as a primitive acquired immune system, which cuts and pastes viral DNA into their own genomes to fight viruses. In recent years, this bacterial system has been adopted by researcher­s to snip out or insert nearly any gene in any organism or cell, quickly and efficientl­y.

“But CRISPR, on its own, is a blunt research tool, since we often have trouble observing or understand­ing the outcome of this genomic editing,” said immunology Prof. Ido Amit, who led the study.

“Most studies so far have looked for black-or-white types of effects,” added Dr. Diego Jaitin, of Amit’s lab group, “but the majority of processes in the body are complex and even chaotic.” The team’s findings have been published in Cell.

Amit and colleagues have been developing the second arm of the new method – single-cell RNA sequencing, a rapidly advancing field that is making an impact on many areas of research and biotechnol­ogy. By sequencing the messenger RNA molecules in each individual cell – messages that indicate cellular activity – the researcher­s are able to uncover the molecular makeup of each cell, and to discern a nuanced range of cell identities and functions in a given cell population. “It is a new molecular microscope,” says Amit. Thousands of cells from a particular tissue in the body can be sequenced at once in his lab, uncovering variation in cell identities and functions. This method has been used to understand everything from the effects of fetal brain developmen­t, to how common immune cells function differentl­y in the various tissues of our body, including their involvemen­t in cancer or neurodegen­eration. But single-cell sequencing has mostly been an observator­y tool, providing a snapshot of a given tissue sample.

Combing CRISPR with the fine resolution of single-cell RNA sequencing can enable researcher­s to actively tinker with the genes in cells, and then to understand their functions within numerous cell types in a variety of situations. The challenge was to adapt the CRISPR gene editing technology so it could be used in combinatio­n with single-cell sequencing.

“The advent of CRISPR presented a true leap in the ability to understand and start editing immune circuits,” concluded Amit. “We are hoping that our approach will be the next leap forward, providing, among other things, the ability to engineer immune cells for immunother­apy.”

NUTS TO YOU FOR IMPROVED HEALTH

People who eat at least 20 grams of nuts per day have a lower risk of heart disease, cancer and other diseases. The analysis of all current studies on nut consumptio­n and disease risk has revealed a handful of nuts can cut people’s risk of coronary heart disease by nearly 30%, of cancer by 15% and of premature death by 22%.

This daily consumptio­n of nuts was also associated with a reduced risk of dying from respirator­y disease by about a half, and diabetes by nearly 40%, although the researcher­s note that there is less data about these diseases in relation to nut consumptio­n. The study, led by researcher­s from Imperial College London and the Norwegian University of Science and Technology, was recently published in the journal BMC Medicine.

The meta-analysis included 29 published studies from around the world that involved up to 819,000 participan­ts, including more than 12,000 cases of coronary heart disease, 9,000 cases of stroke, 18,000 cases of cardiovasc­ular disease and cancer, and more than 85,000 deaths.

While there was some variation between the population­s that were studied, such as between men and women, people living in different regions or people with different risk factors, the researcher­s found that nut consumptio­n was associated with a reduction in disease risk across most of them.

Study co-author Dagfinn Aune said, “We found a consistent reduction in risk across many different diseases, which is a strong indication that there is a real underlying relationsh­ip between nut consumptio­n and different health outcomes. It’s quite a substantia­l effect for such a small amount of food.”

The study included all kinds of tree nuts, such as hazel nuts and walnuts, as well as peanuts – which are actually legumes. The results were in general similar whether total nut intake, tree nuts or peanuts were analyzed. Nuts and peanuts are high in fiber, magnesium, and polyunsatu­rated fats – nutrients that are beneficial for cutting cardiovasc­ular disease risk and can reduce cholestero­l levels. Some nuts, particular­ly walnuts and pecan nuts are also high in antioxidan­ts, which can fight oxidative stress and possibly reduce cancer risk.

Even though nuts are quite high in fat, they are also high in fiber and protein, and there is some evidence that suggests nuts might actually reduce your risk of obesity over time. But don’t exaggerate by eating a whole bag daily; nuts are fattening, too.

Newspapers in English

Newspapers from Israel